Podcast 22 Mar 2024
New treatments being developed for schizophrenia
Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.
Sosei Heptares
- Latest Posts
News and Trends 20 Jul 2023
Sosei Heptares hails ‘transformational’ acquisition
Sosei Group Corporation is set to acquire all shares of Idorsia Pharmaceuticals Japan Ltd (IPJ) and Idorsia Pharmaceuticals Korea Co., Ltd (IPK). The strategic transaction also includes the Japan and APAC territory rights, with the exception of China, to a pipeline of medicines from Idorsia’s portfolio, with lead product PIVLAZ (clazosentan) already commercially available and […]
News and Trends 21 Dec 2022
Pfizer diabetes and obesity study triggers Sosei Heptares windfall
Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment to Sosei Heptares. PF-07081532 is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of type 2 diabetes and obesity. […]
News and Trends 16 Dec 2022
Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases
Sosei Group Corporation has entered a drug discovery collaboration with Eli Lilly and Company to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases. The agreement will leverage Sosei Heptares’ StaR technology and structure-based drug design (SBDD) platform and Lilly’s drug development and commercialization […]
News and Trends 8 Dec 2022
Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders
Sosei Heptares has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, U.K., and KU Leuven, Belgium. Sosei Heptares focuses on G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development. The focus of the agreements is to apply the innovative technologies and research […]
More News! 9 Nov 2022
PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way
PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares, to develop better, more personalized treatment options. Specifically, global techbio PrecisionLife, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, that specializes in structure-based drug design targeting G protein-coupled receptors (GPCRs). Sosei Heptares will leverage […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 5 Aug 2022
Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia
A phase 2 clinical trial for the treatment of schizophrenia has been accepted by the US Food and Drug Administration (FDA) and a study can now go ahead. Neurocrine Biosciences received the news and informed its partner Sosei Group Corporation. The approval of the study of NBI-1117568 has triggered a $30 million payment to Sosei. […]
News and Trends 2 Aug 2022
Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases
A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based Abbvie with the hope of targeting neurological disease. This is the second partnership between the companies and offers the option to license agreement which is aimed at discovering, developing and commercializing small molecules that modulate novel G protein-coupled receptor (GPCR) […]
ADVERTISEMENT